The Department of Defense (DoD) has awarded Microgenics Corporation, a subsidiary of Thermo Electron Corporation, an indefinite delivery contract (IDC) worth up to $5,515,434.90 to provide benzodiazepine immunoassay reagent kits and related laboratory supplies in support of the DoD Drug Demand Reduction Program (DDRP). This single-award IDC has a period of performance through April 30, 2028 and does not utilize any set-aside designations.
Under this IDC, Microgenics has received numerous fixed-price delivery orders from defense agencies such as the Navy Bureau of Medicine and Surgery, Defense Health Agency, and Air Force Air Education and Training Command to fulfill requirements for benzodiazepine reagent kits, opiate reagents, and other toxicology testing products. The products are used to support substance abuse testing and treatment programs at military medical facilities and VA hospitals. Microgenics' manufacturing facilities in California and Illinois will be the primary places of performance for these delivery orders, which have ranged in value from $3,825 to $134,167.50. This contract vehicle and associated task orders aim to provide the DoD with a reliable supply of FDA-cleared immunoassay reagents compatible with their clinical analyzers to meet the requirements of DODI 1010.16 for substance abuse testing.
Generated 1/1/25, 12:09 AM